Diffuse Large B-Cell Lymphoma

ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell Lymphomas
August 09, 2020
ByNirav Niranjan Shah, MD

Nirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.

FDA Approves Tafasitamab, Lenalidomide Combination to Treat Relapsed/Refractory DLBCL
August 03, 2020
ByKristie L. Kahl

The FDA has approved tafasitamab-cxix in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Caron A. Jacobson, MD, on Next Steps for the Phase 2 ZUMA-5 Study
August 02, 2020
ByCaron A. Jacobson, MD

Interim results from the study suggested that axicabtagene ciloleucel (axi-cel) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.